PMO-128 Effects of oral nanoporous carbon therapy in leptin null mice as a model of non-alcoholic steatohepatitis

Macnaughtan, Jane; Soeda, Junpei; Mouralidarane, Angelina; Sandeman, Susan; Howell, Carol; Milkhalovsky, S; Kozynchenko, O.P.; Tennison, S.R.; Davies, N; Mookerjee, Rajeshwar P.; Oben, Jude A.; Jalan, R

doi:10.1136/gutjnl-2012-302514b.128

Cited by 6 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…110 Although the significance of these changes is not clear, the data indicated that alterations to the microenvironment, induced by Yaq-001, change the gut microbial flora. 111 Preliminary studies in rodents with NAFLD show a marked reduction in steatosis and hepatic inflammation. 111 These early observations provide the first indications of the potential of this non-antibiotic, adsorptive strategy.…”

Section: Adsorbentsmentioning

confidence: 99%

“…111 Preliminary studies in rodents with NAFLD show a marked reduction in steatosis and hepatic inflammation. 111 These early observations provide the first indications of the potential of this non-antibiotic, adsorptive strategy. Clinical trials of Yaq-001 are being implemented as a part of the European Commission Horizon 2020 programme (carbalive.eu).…”

Section: Adsorbentsmentioning

confidence: 99%

See 1 more Smart Citation

Targeting the gut-liver axis in liver disease

Wiest

Albillos

Trauner

et al. 2017

Journal of Hepatology

324

337

View full text Add to dashboard Cite

The gut-liver axis is widely implicated in the pathogenesis of liver diseases, where it is increasingly the focus of clinical research. Recent studies trialling an array of therapeutic and preventative strategies have yielded promising results. Considering these strategies, the armamentarium for targeting the gut-liver axis will continue to expand. Further clinical trials, translated from our current knowledge of the gut-liver axis, promise an exciting future in liver treatment.

show abstract

Section: Adsorbentsmentioning

confidence: 99%

Section: Adsorbentsmentioning

confidence: 99%

Targeting the gut-liver axis in liver disease

Wiest

Albillos

Trauner

et al. 2017

Journal of Hepatology

324

337

View full text Add to dashboard Cite

show abstract

“…Yaq-001 can selectively absorb intestinal-derived toxins such as cytokines, hydrophobic bile acid and bacterial products. Oral Yaq-001 therapy revealed a significant reduction in ALT and hepatic TLR-4 expression in rodents with NAFLD [142]. Currently, the clinical trials to assess therapeutic effect of Yaq-001 are under investigation as a part of the European Commission Horizon 2020 program (carbalive.eu) [141].…”

Section: Application Of Adsorbent and Fecal Microbiota Transplantatiomentioning

confidence: 99%

Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives

et al. 2019

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of dysregulated lipid and glucose metabolism, which is often associated with obesity, dyslipidemia and insulin resistance. In view of the high morbidity and health risks of NAFLD, the lack of effective cure has drawn great attention. In recent years, a line of evidence has suggested a close linkage between the intestine and liver diseases such as NAFLD. We summarized the composition and characteristics of intestinal microbes and reviewed molecular insights into the intestinal microbiome in development and progression of NAFLD. Intestinal microbes mainly include bacteria, archaea, viruses and fungi, and the crosstalk between non-bacterial intestinal microbes and human liver diseases should be paid more attention. Intestinal microbiota imbalance may not only increase the intestinal permeability to gut microbes but also lead to liver exposure to harmful substances that promote hepatic lipogenesis and fibrosis. Furthermore, we focused on reviewing the latest ''gut-liver axis''-targeting treatment, including the application of antibiotics, probiotics, prebiotics, synbiotics, farnesoid X receptor agonists, bile acid sequestrants, gut-derived hormones, adsorbents and fecal microbiota transplantation for NAFLD. In this review, we also discussed the potential mechanisms of ''gut-liver axis'' manipulation and efficacy of these therapeutic strategies for NAFLD treatment.

show abstract

“…Adsorbents are poorly absorbable, adsorptive materials that are capable of binding gut-derived toxins and bacterial products, thus abrogating their inflow into the liver and systemic circulation with a consequent reduction in endotoxaemia [ 173 ]. Preliminary studies in rodents with NAFLD show a marked reduction in steatosis and hepatic inflammation: For example, Yaq-001, a synthetic activated carbon with the ability to selectively absorb intestinal-derived toxins (such as cytokines, hydrophobic bile acid and bacterial products) produced a significant reduction in ALT and hepatic TLR-4 expression in rodents with NAFLD [ 174 ]. Currently, clinical trials to assess therapeutic effect of Yaq-001 on humans are under investigation.…”

Section: Therapeutic Potential Of Gut Microbiotamentioning

confidence: 99%

Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut–Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy

Fianchi

Liguori

Gasbarrini

et al. 2021

IJMS

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is the leading cause of liver disease worldwide, affecting both adults and children and will result, in the near future, as the leading cause of end-stage liver disease. Indeed, its prevalence is rapidly increasing, and NAFLD is becoming a major public health concern. For this reason, great efforts are needed to identify its pathogenetic factors and new therapeutic approaches. In the past decade, enormous advances understanding the gut–liver axis―the complex network of cross-talking between the gut, microbiome and liver through the portal circulation―have elucidated its role as one of the main actors in the pathogenesis of NAFLD. Indeed, evidence shows that gut microbiota is involved in the development and progression of liver steatosis, inflammation and fibrosis seen in the context of NAFLD, as well as in the process of hepatocarcinogenesis. As a result, gut microbiota is currently emerging as a non-invasive biomarker for the diagnosis of disease and for the assessment of its severity. Additionally, to its enormous diagnostic potential, gut microbiota is currently studied as a therapeutic target in NAFLD: several different approaches targeting the gut homeostasis such as antibiotics, prebiotics, probiotics, symbiotics, adsorbents, bariatric surgery and fecal microbiota transplantation are emerging as promising therapeutic options.

show abstract

PMO-128 Effects of oral nanoporous carbon therapy in leptin null mice as a model of non-alcoholic steatohepatitis

Cited by 6 publications

References 0 publications

Targeting the gut-liver axis in liver disease

Targeting the gut-liver axis in liver disease

Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives

Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut–Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy

Contact Info

Product

Resources

About